The alpha glucosidase inhibitors market size has grown strongly in recent years. It will grow from $4.22 billion in 2023 to $4.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth observed in the historical period can be attributed to several factors, including a heightened incidence of diabetes, increased awareness of diabetes management, advancements in strategies for treating diabetes, a preference for oral antidiabetic medications, and the influence of clinical research promoting evidence-based medicine.
The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.11 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the forecast period can be attributed to an increasing emphasis on early intervention, a growing geriatric population, global healthcare initiatives aimed at diabetes control, and integration into combination therapies. Major trends expected in the forecast period include patient-centric approaches, a focus on type 2 diabetes management, technological advancements in drug delivery, the emergence of new markets, and globalization, as well as increased collaborations and partnerships within the industry.
The escalating global prevalence of diabetes is anticipated to significantly drive the expansion of the alpha-glucosidase inhibitors market in the foreseeable future. Diabetes, a chronic metabolic condition characterized by elevated blood glucose levels, poses severe risks to various bodily systems, including the heart, blood vessels, eyes, kidneys, and nerves. Alpha-glucosidase inhibitors function by impeding carbohydrate absorption in the small intestine, effectively curbing the surge in postprandial blood glucose levels and aiding in diabetes management. For instance, data from the International Diabetes Federation in November 2022 reported that globally, 537 million adults (equating to 1 in 10 individuals) were afflicted by diabetes. Additionally, projections indicate an anticipated increase in global diabetes prevalence, reaching 643 million by 2030 and 783 million by 2045. Hence, the mounting global incidence of diabetes stands as a key driver fueling the expansion of the alpha-glucosidase inhibitors market.
The expanding demographic shift towards an aging population is anticipated to be a significant catalyst propelling the growth of the alpha-glucosidase inhibitors market. The term 'aging population' signifies a demographic trend characterized by an increasing proportion of elderly individuals within a society or populace. This demographic segment frequently utilizes alpha-glucosidase inhibitors to regulate and manage blood glucose levels, as these medications aid in slowing carbohydrate absorption, offering effective diabetes management - a condition prevalent among older individuals. For instance, data from the World Health Organization (WHO) in October 2022 highlighted a swift rise in the global population of individuals aged 60 years and older, projected to double by 2050, reaching an estimated 2.1 billion individuals. Consequently, the burgeoning aging population serves as a significant driver in fostering growth within the alpha-glucosidase inhibitors market.
A burgeoning trend within the alpha-glucosidase inhibitors market revolves around robust product innovation. Major players in this domain are fervently engaged in pioneering novel products to fortify their market stance. A striking example of this trend emerged in January 2023 when TheracosBio, a distinguished pharmaceutical entity based in the United States, garnered approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin). This innovative oral medication operates as an inhibitor of sodium-glucose cotransporter 2 (SGLT2), specifically tailored for adults grappling with type 2 diabetes. Brenzavvy stands as an adjunct to dietary and exercise regimens, functioning by prompting the kidneys to expel sugar through urine, thereby aiding individuals with type 2 diabetes in effectively managing their blood sugar levels.
Strategic product advancements remains a pivotal strategy adopted by major contenders within the alpha-glucosidase inhibitors market. These companies are diligently crafting inventive solutions such as acarbose tablets to fortify their market foothold. Notably, acarbose stands as an established alpha-glucosidase inhibitor instrumental in the management of type-2 diabetes. In March 2022, Shandong Lukang Pharmaceutical Co. Ltd., an esteemed pharmaceutical entity headquartered in China, unveiled its acarbose tablet in the targeted market. Designed to complement dietary control and exercise programs, these tablets offer significant benefits for individuals coping with type 2 diabetes. Furthermore, they aid in curbing postprandial blood glucose levels in patients afflicted with impaired glucose tolerance, serving as a pivotal addition to the array of treatments available for such conditions.
In April 2023, the pharmaceutical company Sanofi S.A., based in France, successfully acquired Provention Bio Inc. for an undisclosed amount. This strategic move is aimed at broadening Sanofi's diabetes drug portfolio by incorporating TZIELD (teplizumab-mzwv), an innovative and fully owned first-in-class therapy designed for type 1 diabetes. Provention Bio Inc., based in the United States, is recognized for its expertise in the development of diabetes drugs.
Major companies operating in the alpha glucosidase inhibitors market report are Pfizer Inc., Roche, Bayer AG, Novartis AG, Sanofi AS, Bristol Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Novo Nordisk AS, Merck KGaA, Sumitomo Chemical Co. Ltd., C. H. Boehringer Sohn AG and Co. KG, Astellas Pharma, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Biocon, Torrent Pharmaceuticals, Lotus Pharmaceutical Co. Ltd., Anderson Hay and Grain Co. Inc., BioVision Inc., Border Valley Trading, Straight Healthcare, Synjardi XR.
North America was the largest region in the alpha glucosidase inhibitors market in 2023. Middle-East is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha glucosidase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha glucosidase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary applications of alpha-glucosidase inhibitors include addressing dumping syndrome and managing type 2 diabetes. Dumping syndrome encompasses symptoms resulting from swift gastric emptying after meals, leading to a rapid passage of food from the stomach to the duodenum. This acceleration increases sugar levels, and alpha-glucosidase inhibitors play a crucial role in slowing down food digestion, thereby reducing peak blood glucose concentrations post meals. Notable drug classes in this category include acarbose, miglitol, and voglibose, comprising constituents such as glucoamylase, isomaltase, maltase, and sucrase. These medications are distributed through various channels, including online pharmacies, retail pharmacies, and hospital pharmacies.
The alpha-glucosidase inhibitors market research report is one of a series of new reports that provides alpha-glucosidase inhibitors market statistics, including alpha-glucosidase inhibitors industry global market size, regional shares, competitors with an alpha-glucosidase inhibitors market share, detailed alpha-glucosidase inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the alpha-glucosidase inhibitors industry. This alpha-glucosidase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The alpha-glucosidase inhibitors market consists of sales of glucobay and triazolo quinazolines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.11 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the forecast period can be attributed to an increasing emphasis on early intervention, a growing geriatric population, global healthcare initiatives aimed at diabetes control, and integration into combination therapies. Major trends expected in the forecast period include patient-centric approaches, a focus on type 2 diabetes management, technological advancements in drug delivery, the emergence of new markets, and globalization, as well as increased collaborations and partnerships within the industry.
The escalating global prevalence of diabetes is anticipated to significantly drive the expansion of the alpha-glucosidase inhibitors market in the foreseeable future. Diabetes, a chronic metabolic condition characterized by elevated blood glucose levels, poses severe risks to various bodily systems, including the heart, blood vessels, eyes, kidneys, and nerves. Alpha-glucosidase inhibitors function by impeding carbohydrate absorption in the small intestine, effectively curbing the surge in postprandial blood glucose levels and aiding in diabetes management. For instance, data from the International Diabetes Federation in November 2022 reported that globally, 537 million adults (equating to 1 in 10 individuals) were afflicted by diabetes. Additionally, projections indicate an anticipated increase in global diabetes prevalence, reaching 643 million by 2030 and 783 million by 2045. Hence, the mounting global incidence of diabetes stands as a key driver fueling the expansion of the alpha-glucosidase inhibitors market.
The expanding demographic shift towards an aging population is anticipated to be a significant catalyst propelling the growth of the alpha-glucosidase inhibitors market. The term 'aging population' signifies a demographic trend characterized by an increasing proportion of elderly individuals within a society or populace. This demographic segment frequently utilizes alpha-glucosidase inhibitors to regulate and manage blood glucose levels, as these medications aid in slowing carbohydrate absorption, offering effective diabetes management - a condition prevalent among older individuals. For instance, data from the World Health Organization (WHO) in October 2022 highlighted a swift rise in the global population of individuals aged 60 years and older, projected to double by 2050, reaching an estimated 2.1 billion individuals. Consequently, the burgeoning aging population serves as a significant driver in fostering growth within the alpha-glucosidase inhibitors market.
A burgeoning trend within the alpha-glucosidase inhibitors market revolves around robust product innovation. Major players in this domain are fervently engaged in pioneering novel products to fortify their market stance. A striking example of this trend emerged in January 2023 when TheracosBio, a distinguished pharmaceutical entity based in the United States, garnered approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin). This innovative oral medication operates as an inhibitor of sodium-glucose cotransporter 2 (SGLT2), specifically tailored for adults grappling with type 2 diabetes. Brenzavvy stands as an adjunct to dietary and exercise regimens, functioning by prompting the kidneys to expel sugar through urine, thereby aiding individuals with type 2 diabetes in effectively managing their blood sugar levels.
Strategic product advancements remains a pivotal strategy adopted by major contenders within the alpha-glucosidase inhibitors market. These companies are diligently crafting inventive solutions such as acarbose tablets to fortify their market foothold. Notably, acarbose stands as an established alpha-glucosidase inhibitor instrumental in the management of type-2 diabetes. In March 2022, Shandong Lukang Pharmaceutical Co. Ltd., an esteemed pharmaceutical entity headquartered in China, unveiled its acarbose tablet in the targeted market. Designed to complement dietary control and exercise programs, these tablets offer significant benefits for individuals coping with type 2 diabetes. Furthermore, they aid in curbing postprandial blood glucose levels in patients afflicted with impaired glucose tolerance, serving as a pivotal addition to the array of treatments available for such conditions.
In April 2023, the pharmaceutical company Sanofi S.A., based in France, successfully acquired Provention Bio Inc. for an undisclosed amount. This strategic move is aimed at broadening Sanofi's diabetes drug portfolio by incorporating TZIELD (teplizumab-mzwv), an innovative and fully owned first-in-class therapy designed for type 1 diabetes. Provention Bio Inc., based in the United States, is recognized for its expertise in the development of diabetes drugs.
Major companies operating in the alpha glucosidase inhibitors market report are Pfizer Inc., Roche, Bayer AG, Novartis AG, Sanofi AS, Bristol Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Novo Nordisk AS, Merck KGaA, Sumitomo Chemical Co. Ltd., C. H. Boehringer Sohn AG and Co. KG, Astellas Pharma, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Biocon, Torrent Pharmaceuticals, Lotus Pharmaceutical Co. Ltd., Anderson Hay and Grain Co. Inc., BioVision Inc., Border Valley Trading, Straight Healthcare, Synjardi XR.
North America was the largest region in the alpha glucosidase inhibitors market in 2023. Middle-East is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha glucosidase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha glucosidase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary applications of alpha-glucosidase inhibitors include addressing dumping syndrome and managing type 2 diabetes. Dumping syndrome encompasses symptoms resulting from swift gastric emptying after meals, leading to a rapid passage of food from the stomach to the duodenum. This acceleration increases sugar levels, and alpha-glucosidase inhibitors play a crucial role in slowing down food digestion, thereby reducing peak blood glucose concentrations post meals. Notable drug classes in this category include acarbose, miglitol, and voglibose, comprising constituents such as glucoamylase, isomaltase, maltase, and sucrase. These medications are distributed through various channels, including online pharmacies, retail pharmacies, and hospital pharmacies.
The alpha-glucosidase inhibitors market research report is one of a series of new reports that provides alpha-glucosidase inhibitors market statistics, including alpha-glucosidase inhibitors industry global market size, regional shares, competitors with an alpha-glucosidase inhibitors market share, detailed alpha-glucosidase inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the alpha-glucosidase inhibitors industry. This alpha-glucosidase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The alpha-glucosidase inhibitors market consists of sales of glucobay and triazolo quinazolines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Table of Contents
1. Executive Summary2. Alpha Glucosidase Inhibitors Market Characteristics3. Alpha Glucosidase Inhibitors Market Trends and Strategies32. Global Alpha Glucosidase Inhibitors Market Competitive Benchmarking33. Global Alpha Glucosidase Inhibitors Market Competitive Dashboard34. Key Mergers and Acquisitions in the Alpha Glucosidase Inhibitors Market
4. Alpha Glucosidase Inhibitors Market - Macro Economic Scenario
5. Global Alpha Glucosidase Inhibitors Market Size and Growth
6. Alpha Glucosidase Inhibitors Market Segmentation
7. Alpha Glucosidase Inhibitors Market Regional and Country Analysis
8. Asia-Pacific Alpha Glucosidase Inhibitors Market
9. China Alpha Glucosidase Inhibitors Market
10. India Alpha Glucosidase Inhibitors Market
11. Japan Alpha Glucosidase Inhibitors Market
12. Australia Alpha Glucosidase Inhibitors Market
13. Indonesia Alpha Glucosidase Inhibitors Market
14. South Korea Alpha Glucosidase Inhibitors Market
15. Western Europe Alpha Glucosidase Inhibitors Market
16. UK Alpha Glucosidase Inhibitors Market
17. Germany Alpha Glucosidase Inhibitors Market
18. France Alpha Glucosidase Inhibitors Market
19. Italy Alpha Glucosidase Inhibitors Market
20. Spain Alpha Glucosidase Inhibitors Market
21. Eastern Europe Alpha Glucosidase Inhibitors Market
22. Russia Alpha Glucosidase Inhibitors Market
23. North America Alpha Glucosidase Inhibitors Market
24. USA Alpha Glucosidase Inhibitors Market
25. Canada Alpha Glucosidase Inhibitors Market
26. South America Alpha Glucosidase Inhibitors Market
27. Brazil Alpha Glucosidase Inhibitors Market
28. Middle East Alpha Glucosidase Inhibitors Market
29. Africa Alpha Glucosidase Inhibitors Market
30. Alpha Glucosidase Inhibitors Market Competitive Landscape and Company Profiles
31. Alpha Glucosidase Inhibitors Market Other Major and Innovative Companies
35. Alpha Glucosidase Inhibitors Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Alpha Glucosidase Inhibitors Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on alpha glucosidase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for alpha glucosidase inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Type: Dumping Syndrome; Type 2 Diabetes
2) By Drug class: Acarbose; Miglitol; Voglibose
3) By Constituent: Glucoamylase; Isomaltase; Maltase; Sucrase
4) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Hospital Pharmacies
Key Companies Mentioned: Pfizer Inc.; Roche; Bayer AG; Novartis AG; Sanofi AS
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Roche
- Bayer AG
- Novartis AG
- Sanofi AS
- Bristol Myers Squibb Company
- AstraZeneca Plc.
- Takeda Pharmaceutical Co. Ltd.
- Eli Lilly and Company
- Novo Nordisk AS
- Merck KGaA
- Sumitomo Chemical Co. Ltd.
- C. H. Boehringer Sohn AG and Co. KG
- Astellas Pharma
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC
- Glenmark Pharmaceuticals Ltd.
- Biocon
- Torrent Pharmaceuticals
- Lotus Pharmaceutical Co. Ltd.
- Anderson Hay and Grain Co. Inc.
- BioVision Inc.
- Border Valley Trading
- Straight Healthcare
- Synjardi XR
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 4.58 Billion |
| Forecasted Market Value ( USD | $ 6.11 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
